Chronic Kidney Disease associated Pruritus
Conditions
Brief summary
Mean change in weakly mean WI-NRS recorded in the subject’s diary from Baseline to Week 12 for MC2-25 cream compared to MC2-25 vehicle.
Detailed description
Percentage of subjects obtaining a ≥4-point improvement in weekly mean WI-NRS recorded in the subject’s diary from Baseline to Week 12 for MC2-25 cream compared to MC2-25 vehicle., Percentage of subjects obtaining a ≥3-point improvement in weekly mean WI-NRS recorded in the subject’s diary from Baseline to Week 12 for MC2-25 cream compared to MC2-25 vehicle., Percentage of subjects obtaining a complete response in weekly mean WI-NRS recorded in the subject’s diary from Baseline to Week 12 for MC2-25 cream compared to MC2-25 vehicle.
Interventions
Sponsors
Mc2 Therapeutics Limited
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean change in weakly mean WI-NRS recorded in the subject’s diary from Baseline to Week 12 for MC2-25 cream compared to MC2-25 vehicle. | — |
Secondary
| Measure | Time frame |
|---|---|
| Percentage of subjects obtaining a ≥4-point improvement in weekly mean WI-NRS recorded in the subject’s diary from Baseline to Week 12 for MC2-25 cream compared to MC2-25 vehicle., Percentage of subjects obtaining a ≥3-point improvement in weekly mean WI-NRS recorded in the subject’s diary from Baseline to Week 12 for MC2-25 cream compared to MC2-25 vehicle., Percentage of subjects obtaining a complete response in weekly mean WI-NRS recorded in the subject’s diary from Baseline to Week 12 for MC2-25 cream compared to MC2-25 vehicle. | — |
Countries
Germany, Hungary, Poland
Outcome results
None listed